When skin reactions interrupt bone therapy: severe cutaneous adverse reaction to romosozumab leading to treatment discontinuation

Background: Romosozumab is a sclerostin-inhibiting monoclonal antibody that is effective and safe for anabolic treatment in patients with osteoporosis. Its main adverse effects are local; the severity of these injection-site reactions in clinical trials was generally mild. Case report: We present a...

Full description

Bibliographic Details
Published in:	European Journal of Case Reports in Internal Medicine
Main Authors:	Luis Antonio Rodriguez Arrieta, Paola Andrea Rueda Galvis, Miryam Vanessa Rueda Galvis, Samir Alexander Pantoja Meneses, José Manuel Yépez Rodriguez, Francisco Javier Suarez Contreras
Format:	Article
Language:	English
Published:	SMC MEDIA SRL 2025-08-01
Subjects:	adverse drug reaction romosozumab skin reactions osteoporosis monoclonal antibodies
Online Access:	https://www.ejcrim.com/index.php/EJCRIM/article/view/5719

Similar Items

Effects of romosozumab combined with routine therapy on pain relief, disease progression and adverse reactions in patients with postmenopausal osteoporosis: a systematic review and meta-analysis
by: Ge Gao, et al.
Published: (2024-08-01)

Effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patient
by: Bhanvi Ramchandani, et al.
Published: (2024-03-01)

Clinical efficacy of romosozumab in the treatment of elderly male patients of osteoporotic with hip fractures: a retrospective study
by: Yichao Ji, et al.
Published: (2025-01-01)

Profile of romosozumab and its potential in the management of osteoporosis
by: Lim SY, et al.
Published: (2017-04-01)

Romosozumab in osteoporosis: yesterday, today and tomorrow
by: Dong Wu, et al.
Published: (2023-09-01)

A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis
by: Yasumori Sobue, et al.
Published: (2025-07-01)

Papel del Romosozumab en la práctica clínica a la luz de la evidencia
by: Alejandro Román-González, et al.
Published: (2022-01-01)

Romosozumab as Treatment for Severe Osteoporosis in Heart and Lung Transplant Recipients
by: Lisa M. Raven, et al.
Published: (2025-01-01)

Treatment effects, adverse outcomes and cardiovascular safety of romosozumab – Existing worldwide data: A systematic review and meta-analysis
by: Ronald Man Yeung Wong, et al.
Published: (2024-09-01)

Managing delayed union of fragility fractures of the pelvis successfully using romosozumab: A case report
by: K. Wada, et al.
Published: (2025-05-01)

Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment
by: Shi-Hsun Chiu, et al.
Published: (2024-12-01)

Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report
by: Yoichi Kaneuchi, et al.
Published: (2022-12-01)

Monoclonal antibodies in patients with osteoporosis and renal insufficiency: An updated systematic review and meta-analysis
by: Maria L.R. Defante, et al.
Published: (2024-06-01)

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
by: Mingwei Hu, et al.
Published: (2023-07-01)

Diagnosis of skeletal fragility due to Loeys-Dietz syndrome and treatment with romosozumab followed by denosumab
by: Yasutaka Tsujimoto, et al.
Published: (2025-06-01)

Skeletal responses to romosozumab after 12 months of denosumab
by: Michael R. McClung, et al.
Published: (2021-07-01)

Romosozumab and cardiovascular safety in Japan
by: Yasuhiro Takeuchi
Published: (2021-09-01)

Comparison of the Efficacy of Romosozumab and Teriparatide for the Management of Osteoporotic Vertebral Compression Fractures
by: Danbi Park, et al.
Published: (2023-12-01)

Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study
by: Takeshi Mochizuki, et al.
Published: (2021-09-01)

The Real‐World Effect of 12 Months of Romosozumab Treatment on Patients With Osteoporosis With a High Risk of Fracture and Factors Predicting the Rate of Bone Mass Increase: A Multicenter Retrospective Study
by: Hiroyuki Inose, et al.
Published: (2022-07-01)

Comparison of Denosumab with Romosozumab in the treatment of male osteoporosis: a retrospective cohort study
by: Tomonori Kobayakawa, et al.
Published: (2024-10-01)

Examining Romosozumab Adherence and Side Effects in Osteoporotic Patients After Surgical Fracture Fixation: A Comparative, Descriptive, and Hypothesis-Generating Study with Non-Fractured Controls
by: Amarildo Smakaj, et al.
Published: (2025-05-01)

Romosozumab-associated medication-related osteonecrosis of the jaw
by: Benjamin Palla, et al.
Published: (2023-06-01)

Anabolic therapy for osteoporosis: update on efficacy and safety
by: Leonardo Bandeira, et al.
Published: (2022-12-01)

Anti-sclerostin antibody – A potential therapeutic target for periodontal bone regeneration
by: Shruthi Reghunath, et al.
Published: (2024-07-01)

Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study
by: Ki-Hyun Baek, et al.
Published: (2021-02-01)

Comparison of osteoanabolic agents (teriparatide and romosozumab) with bisphosphonates in prevention of subsequent vertebral fractures in patients treated for osteoporotic vertebral fracture for 12 months: An observational cohort study
by: Keishi Maruo, et al.
Published: (2024-06-01)

Role of Anabolic Anti-Osteoporosis Therapy in Diabetes Subjects
by: Harsh Durgia, et al.
Published: (2025-01-01)

Osteoporosis Therapy: Bone Modeling during Growth and Aging
by: Toshihiro Sugiyama, et al.
Published: (2017-03-01)

Development of a novel macroscopic regulation and microscopic intervention mode nanosystem for osteoporosis treatment
by: Shichao Meng, et al.
Published: (2025-06-01)

Five-Year Sales Trends of Osteoporosis Medications in Korea: A Market Analysis Based on IMS Health Sales Audit Data (2018–2023)
by: Jung Yoon Park, et al.
Published: (2025-04-01)

Comparison of the Clinical Efficacy of Anabolic Agents and Bisphosphonates in the Patients With Osteoporotic Vertebral Fracture: Systematic Review and Meta-analysis of Randomized Controlled Trials
by: Ikchan Jeon, et al.
Published: (2024-06-01)

Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO)
by: Barbara C. Silva, et al.
Published: (2022-10-01)

Therapeutic Drug Review on Romosozumab: The First Sclerostin Inhibitor
by: Vijay Kumar Jain, et al.
Published: (2022-04-01)

High-dose romosozumab promoted bone regeneration of critical-size ulnar defect filled with demineralized bone matrix in nonhuman primates
by: Xiaodong Li, et al.
Published: (2025-09-01)

Comparative Analysis of Romosozumab Versus Vertebroplasty With Denosumab: Efficacy, Safety, and Secondary Bone Mineral Density Outcomes
by: Hyun Woong Mun, et al.
Published: (2025-03-01)

A cross-sectional study of adverse cutaneous drug reactions with special reference to reaction time
by: P Deepthi, et al.
Published: (2022-01-01)

Late reaction, persistent reaction and doubtful allergic reaction: The problems of interpretation
by: Sarma Nilendu
Published: (2009-01-01)

Hypersensitivity Reactions to Monoclonal Antibodies in Children
by: Francesca Mori, et al.
Published: (2020-05-01)

Interrupted Nef and Meyer Reactions: A Growing Point for Diversity-Oriented Synthesis Based on Nitro Compounds
by: Alexey Yu. Sukhorukov
Published: (2023-01-01)